Biotecnologia em saúde humana no Brasil: produção científica e pesquisa e desenvolvimento

Torres-Freire, Carlos Eduardo; Golgher, Denise; Callil, Victor

doi:10.1590/s0101-33002014000100005

Cited by 13 publications

(6 citation statements)

References 12 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a consequence, there is a deficit in the trade balance, which was US $7.64 billion in 2011, of which US $2.6 billion was due to the import deficit of drugs, US $2.3 billion of API, US $500 million from imports of vaccines and the remainder corresponds to the import of serum, diagnostic reagents and blood products. Biotechnology‐based products, such as insulin, contribute heavily to the increase in the balance deficit, since in recent years, imports of organic products have grown on average 37% per year …”

Section: Methodsmentioning

confidence: 99%

Market for biotechnology drugs: market analysis of insulin

Pontes

Barroso

Rito

2018

J Pharm Health Serv Res

View full text Add to dashboard Cite

Objectives The aim of the present study was to present the market scenario of biotechnological drugs, especially insulin. In addition to Brazil, a study was conducted that considered the United States market, which has the largest market of biotechnological products in the world and in China, for presenting an increase in investments in the biotechnology area and is a BRICS member. Methods A market survey of biotechnological drugs and insulin was carried out. The information that was used is provided through the IMS Health Customer Portal from 2010 to 2014, and was searched in the AliceWeb database between 2011 and 2016, and we consulted Insights magazine (published by IMS Health). Information was also obtained from the Brazilian Association of the Pharmaceutical and Pharmaceutical Industries (Abiquif) (2012–2016) and from the International Diabetes Federation (IDF), available on its websites, to identify sales of biotech drugs and, more specifically, insulin. Key findings The deficit in the Brazilian trade balance between 2012 and 2016, related to medicines, remains high, mainly driven by the acquisition of high value‐added drugs, mainly biotechnological drugs, such as insulin. In 5 years (2010–2014), the value of the commercialization of insulin increased by an average of 100%. In 2010, the total marketing value of insulin was approximately US $16 billion, and in 2014, it was approximately US $29 billion. The three laboratories that stand out in the world, namely, Sanofi, Lilly and Novo Nordisk, are the main laboratories that market insulin in Brazil. Conclusions The observed results make evident the import dependence for the acquisition of insulin, which can lead to a national shortage and possible cases of death and sequelae from diabetes in patients who did not receive adequate treatment, besides contributing to the trade deficit.

show abstract

Section: Methodsmentioning

confidence: 99%

Market for biotechnology drugs: market analysis of insulin

Pontes

Barroso

Rito

2018

J Pharm Health Serv Res

View full text Add to dashboard Cite

show abstract

“…Torres-Freire et al [27] observed that the economic activity involving biotechnology has high technological intensity and does not develop without communication between private (companies), public (governments/agents), and academic (institutions / universities) sectors. This integration refers to "Triple Helix" concept, which proposes a dynamic relationship between state and science conducted in universities and materialized by technology developed in companies [28] (p. 112).…”

Section: Theorical Backgroundmentioning

confidence: 99%

Scientific Production on Technological Cooperation Networks in Biotechnology sector

JMSd¹,

Pr²,

Pigola³

et al. 2021

Preprint

View full text Add to dashboard Cite

The present study aims to analyze scientific production about technological cooperation networks in biotechnology sector, based on bibliometrics network analysis. We used the Gephi software to identify groups of partnerships, proving that the cooperation relationship is a practice used, re-sulting technological development. Findings identify that in the path for new resources that com-plement skills and competences universities are an important player in this cooperative ecosystem, and The United States is a large hub, with an extensive network of global cooperation. A strong role of its researchers in the publication of scientific articles in cooperation is highlighted. This study contributes to the advancement of the discussion about cooperative networks, as well as to the development of policies aimed at the biotechnology sector advancements

show abstract

“…O crescente número de patentes em biotecnologia para a saúde pode ser associado à expansão dos programas de pós-graduação na área, os quais têm vinculado a defesa de dissertação e teses a pedidos de depósitos de patentes (Costa, Florencio & Oliveira Júnior, 2018). Aliado a isso, o Brasil apresenta um grande mercado na área de saúde, com demanda ascendente por produtos de base biotecnológica, tais como os medicamentos e insumos farmoquímicos, que geraram um déficit na balança comercial de quase US$ 5 bilhões em 2011 (Freire, Golgher & Callil, 2014).…”

Section: Biotecnologia Para a Saúdeunclassified

Desenvolvimento tecnológico da biotecnologia para a saúde no Brasil

2020

View full text Add to dashboard Cite

Objective of the study: This study aims to analyze the technological development of health biotechnology in Brazil in the period from 2007 to 2016.Methodology: The research methodology was based on a quantitative approach with the application of statistical methods aligned with patent analysis. Data collection was carried out on the institutional page of the National Institute of Industrial Property (INPI). The health biotechnology patents were classified according to the definitions presented by the Biotechnology Development Policy (PDB).Originality/Relevance: This study brings new contributions to the literature on the technological development of biotechnology when dealing with the sectoral level.Main results: The results obtained showed a total of 503 patents granted, with applications that mostly involve human health (70%). The development of drugs for the treatment of metabolic or endocrinological diseases is notorious, while vaccines have greater applications in the prevention of veterinary diseases. Also, patent ownership belongs mostly to large companies in developed countries.Theoretical/methodological contributions: The study deepened the understanding of the technological development of biotechnology in Brazil using patent indicators and allowed us to understand this dynamic in the sectorial context involving health.Social/managerial contributions: The statistics of patents in health biotechnology can assist policymakers in practices aimed at promoting research, development, and innovation activities with applications in health.

show abstract

Biotecnologia em saúde humana no Brasil: produção científica e pesquisa e desenvolvimento

Cited by 13 publications

References 12 publications

Market for biotechnology drugs: market analysis of insulin

Market for biotechnology drugs: market analysis of insulin

Scientific Production on Technological Cooperation Networks in Biotechnology sector

Desenvolvimento tecnológico da biotecnologia para a saúde no Brasil

Contact Info

Product

Resources

About